Teva Announces Updated Time For Webcast To Discuss Study Results On April
                              12th, 01:00 a.m. CET

-         Phase III ALLEGRO study met primary endpoint and key secondary
o        23 percent reduction in annualized relapse rate
o        36 percent reduction in sustained disability progression
o        33 percent reduction in brain atrophy
o        Safe and well-tolerated therapy without immunosuppressive effects
-         Additional new pre-clinical data demonstrate potential neuroprotective
mechanism of action of laquinimod

Jerusalem, Israel and Lund, Sweden, April 12, 2011 - Teva Pharmaceutical
Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)
announced today results from the two-year Phase III ALLEGRO study of laquinimod,
an oral, once-daily, investigational immunomodulator for the treatment of
relapsing forms of multiple sclerosis (MS). These data will be presented as
late-breaking research at the Annual Meeting of the American Academy of
Neurology (AAN).

In  the ALLEGRO study, laquinimod  showed a statistically significant 23 percent
reduction  in annualized  relapse rate  (p=0.0024), the  primary endpoint, along
with  a significant  36 percent reduction  in the  risk of  confirmed disability
progression,  as measured by Expanded Disability Status Scale (EDSS) (p=0.0122).
Treatment  with laquinimod was  also associated with  a significant reduction in
brain tissue loss, as measured by a 33 percent reduction in progression of brain
atrophy (p<0.0001).

"The ALLEGRO study results are exciting, as they suggest that oral laquinimod is
a novel therapeutic option that safely slows MS disease activity and
progression," said Principal Investigator, Professor Giancarlo Comi, Director of
the Department of Neurology and Institute of Experimental Neurology at the
University Vite Salute, San Raffaele, Italy. "Additional pre-clinical data
presented at this meeting suggest that oral laquinimod exerts a novel and
protective mechanism of action within the central nervous system to
significantly reduce the main neurological damage of the disease."

Laquinimod  was safe  and well-tolerated  without immunosuppressive effects. The
overall  frequencies of adverse events,  including incidence of infections, were
comparable  to those observed  in the placebo  group. The most commonly reported
adverse  events were headaches, nasopharyngitis and  back pain. The incidence of
liver enzyme elevation was higher in laquinimod treated patients; however, these
elevations  were transient, asymptomatic and reversible. No deaths were reported
in laquinimod-treated patients.

The  positive  ALLEGRO  results  are  supported  by  new pre-clinical data, also
presented  at the  AAN meeting,  that further  establish the mechanism of action
(MOA)  of  laquinimod,  which  led  to  a  reduction  in axonal damage, the main
determinant  of permanent  clinical disability  in MS.  Data from  the cuprizone
model,  designed to investigate the  effect on neurodegeneration, independent of
inflammation,  demonstrated  that  laquinimod  reduced  demyelination and axonal
damage while preserving more myelin-producing cells. This unique effect suggests
a  direct  decrease  in  nerve  damage  in  the  central  nervous  system (CNS).
Additionally,  laquinimod was  shown to  modulate the brain-derived neurotrophic
factor (BDNF) pathway, a key factor in maintaining axonal integrity.

"We are very enthusiastic about the results of the ALLEGRO study, which
demonstrated that laquinimod significantly slows the progression of disability,
the primary goal of MS treatment. Given the efficacy, safety and tolerability
data to date, laquinimod may present a very promising treatment option to the MS
community," said Professor Yitzhak Peterburg, Teva's Group Vice President,
Global Branded Products.

The  second laquinimod Phase III study, BRAVO, is currently ongoing with results
anticipated  in the third quarter of 2011. Regulatory submissions are planned in
the U.S. and the EU following the availability of the BRAVO results.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host an audio webcast on
April  11(th), 2011 at 7:00 p.m. EDT  to present the  results from the Phase III
ALLEGRO study of laquinimod. Those interested in listening to the webcast should
log  on  to  http://www.tevapharm.com/financial/ and  register  for  the  event
(approximately 10 minutes before).  The dial-in for this call is 1-800-215-2410
or  617-597-5410 internationally. The conference ID  or passcode is 14479443. An
archive of the webcast will be available on Teva's website.

ALLEGRO  was a  two-year multi-national,  multi-center randomized, double blind,
placebo-controlled   study   designed  to  evaluate  the  efficacy,  safety  and
tolerability  of laquinimod in MS patients. The study was conducted at 139 sites
in  24 countries  and  enrolled  1,106 MS  patients. Patients were randomized to
receive  a once-daily  oral dose  of 0.6 mg  laquinimod or matching placebo. The
primary outcome measure was the number of confirmed relapses; secondary measures
included confirmed disability progression and changes in MRI active lesions.

Eighty  percent of laquinimod  and 77 percent of  placebo patients completed the
two-year study. Patients who completed the ALLEGRO study were offered to join an
open-label extension phase, in which they are being treated with laquinimod 0.6
mg daily.

Laquinimod  is an  oral, once-daily,  immunomodulator with  a novel mechanism of
action  being developed for the  treatment of MS. The  global Phase III clinical
development  program evaluating  oral laquinimod  in MS  consists of two pivotal
studies,  ALLEGRO and BRAVO. BRAVO, is a two-year, multi-national, multi-center,
randomized,  double-blind, parallel-group, placebo-controlled  study designed to
compare  the safety, efficacy and tolerability of a once-daily oral dose of 0.6
mg  laquinimod over placebo and to perform a comparative risk-benefit assessment
between  laquinimod and interferon beta-1a. Enrollment of 1,332 patients at 154
sites  in the U.S, Europe, Israel and  South Africa was completed in June 2009.
BRAVO study results are anticipated in the third quarter of 2011.

In addition to the ongoing MS clinical studies, laquinimod is currently in Phase
II  development for  Crohn's disease  and Lupus,  and is  being studied in other
autoimmune diseases.

MS  is  the  leading  cause  of  neurological  disability in young adults. It is
estimated that more than 400,000 people in the United States are affected by the
disease  and  that  two  million  people  may  be  affected  worldwide. Multiple
sclerosis  is  a  degenerative  disease  of  the central nervous system in which
inflammation and axonal damage and loss result in the development of progressive

Teva   Pharmaceutical   Industries   Ltd.  (NASDAQ:TEVA)  is  a  leading  global
pharmaceutical   company,   committed   to  increasing  access  to  high-quality
healthcare  by developing, producing  and marketing affordable  generic drugs as
well  as  innovative  and  specialty  pharmaceuticals  and active pharmaceutical
ingredients.  Headquartered in Israel, Teva is  the world's largest generic drug
maker, with a global product portfolio of more than 1,450 molecules and a direct
presence  in  60 countries.  Teva's  branded  businesses  focus on neurological,
respiratory  and women's health  therapeutic areas as  well as biologics. Teva's
leading  innovative product, Copaxone(®), is the number one prescribed treatment
for  multiple  sclerosis.  Teva  employs  approximately 40,000 people around the
world and reached $16.1 billion in net sales in 2010.

Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases  and cancer. Projects  in or entering
pivotal  phase are laquinimod, an orally administered small molecule with unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer as well as ANYARA for use in cancer targeted therapy, primarily
of  renal cell cancer.  In addition, laquinimod  is in Phase  II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visit www.activebiotech.comfor more information.

Teva's  Safe  Harbor  Statement  under  the  U. S. Private Securities Litigation
Reform Act of 1995:
This  release  contains  forward-looking  statements,  which express the current
beliefs   and   expectations   of  management.  Such  statements  are  based  on
management's  current beliefs and expectations and involve a number of known and
unknown risks and uncertainties that could cause our future results, performance
or  achievements  to  differ  significantly  from  the  results,  performance or
achievements  expressed or implied by such forward-looking statements. Important
factors  that  could  cause  or  contribute  to  such  differences include risks
relating  to: our ability  to successfully develop  and commercialize additional
pharmaceutical  products, the introduction of competing generic equivalents, the
extent  to which we  may obtain U.S.  market exclusivity for  certain of our new
generic  products  and  regulatory  changes  that  may prevent us from utilizing
exclusivity  periods, potential liability for sales of generic products prior to
a  final resolution of outstanding patent litigation, including that relating to
the  generic versions of Neurontin®, Lotrel®,  Protonix® and Gemzar®, the extent
to which any manufacturing or quality control problems damage our reputation for
high  quality production, the effects of  competition on sales of our innovative
products, especially Copaxone® (including potential generic and oral competition
for  Copaxone®), the impact of continuing  consolidation of our distributors and
customers,  our  ability  to  identify,  consummate  and  successfully integrate
acquisitions  (including the  acquisition of  ratiopharm), interruptions  in our
supply  chain or problems with our information technology systems that adversely
affect our complex manufacturing processes, intense competition in our specialty
pharmaceutical  businesses, any failures to comply with the complex Medicare and
Medicaid   reporting   and   payment   obligations,  our  exposure  to  currency
fluctuations and restrictions as well as credit risks, the effects of reforms in
healthcare  regulation, adverse effects of  political or economical instability,
major  hostilities or acts of terrorism on our significant worldwide operations,
increased government scrutiny in both the U.S. and Europe of our agreements with
brand  companies,  dependence  on  the  effectiveness  of  our patents and other
protections  for innovative  products, our  ability to  achieve expected results
through  our innovative R&D efforts, the  difficulty of predicting U.S. Food and
Drug  Administration, European  Medicines Agency  and other regulatory authority
approvals,  uncertainties surrounding the legislative and regulatory pathway for
the  registration  and  approval  of  biotechnology-based  products, potentially
significant  impairments of intangible assets  and goodwill, potential increases
in  tax liabilities resulting from  challenges to our intercompany arrangements,
our  potential exposure to product liability claims to the extent not covered by
insurance,  the  termination  or  expiration  of  governmental  programs  or tax
benefits, current economic conditions, any failure to retain key personnel or to
attract  additional  executive  and  managerial  talent, environmental risks and
other  factors that are discussed  in this report and  in our other filings with
the U.S. Securities and Exchange Commission.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:
This press release contains certain forward-looking statements. Such forward-
looking statements involve known and unknown risks, uncertainties and other
important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from any
future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or publicly
release any revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press release.

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication on April 12, 2011, at 7:30 a.m.
                                       # # #


This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE